샘플 요청 목록

 카트 문의
시장보고서
상품코드
1874402

세계의 시신경 척수염(NMO) 치료제 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

Neuromyelitis Optica Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 시신경 척수염(NMO) 치료제 시장 규모는 2024년에 4,980만 달러로 추정되며, 2025-2031년의 예측 기간에 CAGR 3.0%로 성장을 지속하여, 2031년까지 6,110만 달러로 확대될 것으로 예측됩니다.

시신경 척수염(NMO)은 중추신경계(CNS)에 발생하는 희귀질환 증후군으로 시신경과 척수에 영향을 미치는 질환입니다. NMO 환자는 시신경염을 일으켜 눈의 통증과 시력 저하를 유발합니다. 또한 횡단성 척수염에 걸리면 팔과 다리의 근력저하, 마비, 때로는 마비가 발생하며, 감각장애와 방광 및 장의 기능장애를 동반할 수 있습니다. NMO는 신경섬유를 덮고 신경 신호의 세포 간 전달을 돕는 지방성 물질인 미엘린의 손실을 유발합니다. 이 증후군은 신경 섬유를 손상시키고 괴사된 조직 부위를 남길 수 있습니다. NMO의 병태생리에서 아직 명확하지 않은 이유로 면역계 세포와 항체가 시신경과 척수의 미엘린 세포를 공격하고 파괴합니다. 시신경척수염 치료제는 시신경척수염 치료에 사용되는 약물로, 본 보고서에서는 메틸프레드니솔론과 같은 당질 코르티코이드와 IVIg와 같은 면역글로불린에 초점을 맞추었습니다.

시신경 척수염(NMO) 치료제 시장은 이 희귀 자가면역질환(일명 시신경척수염 스펙트럼 장애(NMOSD)의 유병률 증가와 진단 정확도 향상으로 인해 크게 견인되고 있습니다. 의료진의 인식 개선과 더불어 AQP4-IgG 항체 검사 등 진단 기술의 발전으로 NMO를 조기에 정확하게 진단할 수 있게 되어 치료 대상 환자 수가 증가하고 있습니다. 또한, 최근 승인된 에크리주맙, 이네비리주맙, 사트랄리주맙과 같은 표적치료제는 기존 면역억제제에 비해 더 효과적이고 특이적인 치료법을 제공함으로써 치료 환경을 변화시켰습니다. 이러한 획기적인 발전은 환자의 예후를 개선했을 뿐만 아니라, NMO 치료제 개발에 대한 투자와 혁신을 촉진하고 있습니다. 희귀질환에 대한 제약사들의 관심이 높아지면서 희귀질환 치료제 지정 및 패스트트랙 승인과 같은 유리한 규제적 인센티브가 시장 성장을 더욱 가속화하고 있습니다. 또한, 특히 선진국의 의료비 지출 증가와 환자 지원 활동의 강화는 과거에는 간과되었던 이 질환에 대한 치료 접근성 확대와 인식 개선에 기여하고 있습니다.

NMO 치료제 시장은 유망한 진전을 보이고 있지만, 장기적인 성장을 저해할 수 있는 몇 가지 문제에 직면해 있습니다. 첫째, 새로 승인된 생물학적 제제의 높은 비용은 특히 중저소득 국가들, 특히 취약하거나 존재하지 않는 상환제도가 있는 국가들에서 접근성에 심각한 장벽이 되고 있습니다. 에크리주맙과 같은 약품의 가격(연간 수십만 달러에 달하는 경우도 있음)은 의료 시스템과 환자 모두에게 큰 부담을 주기 때문에 보급에 걸림돌이 될 수 있습니다. 또한, NMO는 희귀하고 복잡한 질환이기 때문에 대규모 임상시험에 필요한 충분한 피험자를 확보하기 어려워 약물 개발 및 혁신의 속도를 늦추고 있습니다. 질병의 표현형의 다양성과 다발성 경화증과의 증상 중첩도 진단상의 문제로 오진이나 부적절한 치료로 이어질 수 있습니다. 또한, 새로운 치료법의 장기 안전성 데이터는 여전히 제한적이어서 임상의와 규제 당국이 이러한 치료법을 더 광범위하게 채택하는 데 주저할 수 있습니다. 마지막으로, 시장은 여전히 고도로 전문화되어 있고, 진입하는 제약기업이 적기 때문에 경쟁이 제한적이고 공급망 취약성이 우려됩니다. 최근 NMO 치료의 발전이 다양한 의료 환경에서 환자의 치료 결과를 개선하기 위해서는 이러한 문제를 해결하는 것이 필수적입니다.

이 보고서는 시신경척수염 치료제 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

본 보고서의 신경척수염 치료제 시장 규모 추정 및 예측은 매출액 기준으로 제시되며, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적, 정성적 분석을 통해 독자들이 신경척수염 치료제 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 포지셔닝 분석, 정보에 입각한 사업적 판단을 내릴 수 있도록 도와드립니다.

시장 세분화

기업별

  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

유형별 부문

  • 당질 코르티코이드
  • 면역치료
  • 기타

용도별 부문

  • 급성 발작
  • 관해 예방 치료

지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 동남아시아
    • 인도
    • 호주
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 네덜란드
    • 북유럽 국가
    • 기타 유럽
  • 라틴아메리카
    • 멕시코
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 튀르키예
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 기타 중동 및 아프리카
LSH 25.12.08

자주 묻는 질문

  • 시신경 척수염(NMO) 치료제 시장 규모는 어떻게 예측되나요?
  • 시신경 척수염(NMO) 치료제 시장의 주요 기업은 어디인가요?
  • 시신경 척수염(NMO) 치료제의 주요 유형은 무엇인가요?
  • 시신경 척수염(NMO) 치료제의 용도는 어떻게 나뉘나요?
  • NMO 치료제 시장의 성장 요인은 무엇인가요?
  • NMO 치료제 시장이 직면한 문제는 무엇인가요?

The global market for Neuromyelitis Optica Drug was estimated to be worth US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 61.1 million by 2031 with a CAGR of 3.0% during the forecast period 2025-2031.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.

Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.

This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Neuromyelitis Optica Drug by region & country, by Type, and by Application.

The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.

Market Segmentation

By Company

  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

Segment by Type

  • Glucocorticoids
  • Immunotherapies
  • Others

Segment by Application

  • Acute Attack
  • Remission Prophylactic Treatment

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Neuromyelitis Optica Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Neuromyelitis Optica Drug in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Neuromyelitis Optica Drug Product Introduction
  • 1.2 Global Neuromyelitis Optica Drug Market Size Forecast (2020-2031)
  • 1.3 Neuromyelitis Optica Drug Market Trends & Drivers
    • 1.3.1 Neuromyelitis Optica Drug Industry Trends
    • 1.3.2 Neuromyelitis Optica Drug Market Drivers & Opportunity
    • 1.3.3 Neuromyelitis Optica Drug Market Challenges
    • 1.3.4 Neuromyelitis Optica Drug Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Neuromyelitis Optica Drug Players Revenue Ranking (2024)
  • 2.2 Global Neuromyelitis Optica Drug Revenue by Company (2020-2025)
  • 2.3 Key Companies Neuromyelitis Optica Drug Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Neuromyelitis Optica Drug Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Neuromyelitis Optica Drug
  • 2.6 Neuromyelitis Optica Drug Market Competitive Analysis
    • 2.6.1 Neuromyelitis Optica Drug Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Neuromyelitis Optica Drug Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Glucocorticoids
    • 3.1.2 Immunotherapies
    • 3.1.3 Others
  • 3.2 Global Neuromyelitis Optica Drug Sales Value by Type
    • 3.2.1 Global Neuromyelitis Optica Drug Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Neuromyelitis Optica Drug Sales Value, by Type (2020-2031)
    • 3.2.3 Global Neuromyelitis Optica Drug Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Acute Attack
    • 4.1.2 Remission Prophylactic Treatment
  • 4.2 Global Neuromyelitis Optica Drug Sales Value by Application
    • 4.2.1 Global Neuromyelitis Optica Drug Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Neuromyelitis Optica Drug Sales Value, by Application (2020-2031)
    • 4.2.3 Global Neuromyelitis Optica Drug Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Neuromyelitis Optica Drug Sales Value by Region
    • 5.1.1 Global Neuromyelitis Optica Drug Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025)
    • 5.1.3 Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031)
    • 5.1.4 Global Neuromyelitis Optica Drug Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.2.2 North America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.3.2 Europe Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Neuromyelitis Optica Drug Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.5.2 South America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Neuromyelitis Optica Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Neuromyelitis Optica Drug Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.3.2 United States Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.4.2 Europe Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.5.2 China Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.6.2 Japan Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.7.2 South Korea Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.9.2 India Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Pfizer
    • 7.1.1 Pfizer Profile
    • 7.1.2 Pfizer Main Business
    • 7.1.3 Pfizer Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.1.4 Pfizer Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Pfizer Recent Developments
  • 7.2 Fresenius
    • 7.2.1 Fresenius Profile
    • 7.2.2 Fresenius Main Business
    • 7.2.3 Fresenius Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.2.4 Fresenius Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Fresenius Recent Developments
  • 7.3 Teva
    • 7.3.1 Teva Profile
    • 7.3.2 Teva Main Business
    • 7.3.3 Teva Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.3.4 Teva Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Teva Recent Developments
  • 7.4 Sandoz
    • 7.4.1 Sandoz Profile
    • 7.4.2 Sandoz Main Business
    • 7.4.3 Sandoz Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.4.4 Sandoz Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Sandoz Recent Developments
  • 7.5 Intas
    • 7.5.1 Intas Profile
    • 7.5.2 Intas Main Business
    • 7.5.3 Intas Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.5.4 Intas Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Intas Recent Developments
  • 7.6 Gyjtrs
    • 7.6.1 Gyjtrs Profile
    • 7.6.2 Gyjtrs Main Business
    • 7.6.3 Gyjtrs Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Gyjtrs Recent Developments
  • 7.7 NANG KUANG
    • 7.7.1 NANG KUANG Profile
    • 7.7.2 NANG KUANG Main Business
    • 7.7.3 NANG KUANG Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.7.5 NANG KUANG Recent Developments
  • 7.8 Tianjin Kingyork
    • 7.8.1 Tianjin Kingyork Profile
    • 7.8.2 Tianjin Kingyork Main Business
    • 7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Tianjin Kingyork Recent Developments
  • 7.9 Baxter
    • 7.9.1 Baxter Profile
    • 7.9.2 Baxter Main Business
    • 7.9.3 Baxter Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.9.4 Baxter Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Baxter Recent Developments
  • 7.10 CSL
    • 7.10.1 CSL Profile
    • 7.10.2 CSL Main Business
    • 7.10.3 CSL Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.10.4 CSL Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.10.5 CSL Recent Developments
  • 7.11 Grifols
    • 7.11.1 Grifols Profile
    • 7.11.2 Grifols Main Business
    • 7.11.3 Grifols Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.11.4 Grifols Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Grifols Recent Developments
  • 7.12 Octapharma
    • 7.12.1 Octapharma Profile
    • 7.12.2 Octapharma Main Business
    • 7.12.3 Octapharma Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.12.4 Octapharma Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Octapharma Recent Developments
  • 7.13 CBOP
    • 7.13.1 CBOP Profile
    • 7.13.2 CBOP Main Business
    • 7.13.3 CBOP Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.13.4 CBOP Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.13.5 CBOP Recent Developments

8 Industry Chain Analysis

  • 8.1 Neuromyelitis Optica Drug Industrial Chain
  • 8.2 Neuromyelitis Optica Drug Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Neuromyelitis Optica Drug Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Neuromyelitis Optica Drug Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제